Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies

Nicole O'Brien, S. Tarran Jones, David G. Williams, H. Brad Cunningham, Kelli Moreno, Barbara Visentin, Angela Gentile, John Vekich, William Shestowsky, Masao Hiraiwa, Rosalia Matteo, Amy Cavalli, Douglas Grotjahn, Maria Grant, Geneviève Hansen, Mary Ann Campbell, Roger Sabbadini

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid involved in multiple physiological processes. Importantly, dysregulated S1P levels are associated with several pathologies, including cardiovascular and inflammatory diseases and cancer. This report describes the successful production and characterization of a murine monoclonal antibody, LT1002, directed against S1P, using novel immunization and screening methods applied to bioactive lipids. We also report the successful generation of LT1009, the humanized variant of LT1002, for potential clinical use. Both LT1002 and LT1009 have high affinity and specificity for S1P and do not cross-react with structurally related lipids. Using an in vitro bioassay, LT1002 and LT1009 were effective in blocking S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells, showing that both antibodies can outcompete S1P receptors in binding to S1P. In vivo anti-angiogenic activity of all antibody variants was demonstrated using the murine choroidal neovascularization model. Importantly, intravenous administration of the antibodies showed a marked effect on lymphocyte trafficking. The resulting lead candidate, LT1009, has been formulated for Phase 1 clinical trials in cancer and age-related macular degeneration. The anti-S1P antibody shows promise as a novel, first-in-class therapeutic acting as a "molecular sponge" to selectively deplete S1P from blood and other compartments where pathological S1P levels have been implicated in disease progression or in disorders where immune modulation may be beneficial.

Original languageEnglish (US)
Pages (from-to)2245-2257
Number of pages13
JournalJournal of Lipid Research
Volume50
Issue number11
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Antibodies
Lipids
Lysosphingolipid Receptors
Physiological Phenomena
Immunization
sphingosine 1-phosphate
Choroidal Neovascularization
Clinical Trials, Phase I
Lymphocytes
Bioassay
Intravenous Immunoglobulins
Immune System Diseases
Macular Degeneration
Porifera
Pathology
Interleukin-8
Biological Assay
Intravenous Administration
Disease Progression
Neoplasms

Keywords

  • Age related macular degeneration
  • Angiogenesis
  • Bioactive lipids
  • Cancer
  • Choroidal neovascularization
  • Complementarity determining region
  • Humanization
  • Lymphocyte trafficking
  • Monoclonal antibodies
  • Sphingosine-1-phosphate

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Endocrinology

Cite this

O'Brien, N., Jones, S. T., Williams, D. G., Cunningham, H. B., Moreno, K., Visentin, B., ... Sabbadini, R. (2009). Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. Journal of Lipid Research, 50(11), 2245-2257. https://doi.org/10.1194/jlr.M900048-JLR200

Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. / O'Brien, Nicole; Jones, S. Tarran; Williams, David G.; Cunningham, H. Brad; Moreno, Kelli; Visentin, Barbara; Gentile, Angela; Vekich, John; Shestowsky, William; Hiraiwa, Masao; Matteo, Rosalia; Cavalli, Amy; Grotjahn, Douglas; Grant, Maria; Hansen, Geneviève; Campbell, Mary Ann; Sabbadini, Roger.

In: Journal of Lipid Research, Vol. 50, No. 11, 2009, p. 2245-2257.

Research output: Contribution to journalArticle

O'Brien, N, Jones, ST, Williams, DG, Cunningham, HB, Moreno, K, Visentin, B, Gentile, A, Vekich, J, Shestowsky, W, Hiraiwa, M, Matteo, R, Cavalli, A, Grotjahn, D, Grant, M, Hansen, G, Campbell, MA & Sabbadini, R 2009, 'Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies', Journal of Lipid Research, vol. 50, no. 11, pp. 2245-2257. https://doi.org/10.1194/jlr.M900048-JLR200
O'Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. Journal of Lipid Research. 2009;50(11):2245-2257. https://doi.org/10.1194/jlr.M900048-JLR200
O'Brien, Nicole ; Jones, S. Tarran ; Williams, David G. ; Cunningham, H. Brad ; Moreno, Kelli ; Visentin, Barbara ; Gentile, Angela ; Vekich, John ; Shestowsky, William ; Hiraiwa, Masao ; Matteo, Rosalia ; Cavalli, Amy ; Grotjahn, Douglas ; Grant, Maria ; Hansen, Geneviève ; Campbell, Mary Ann ; Sabbadini, Roger. / Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. In: Journal of Lipid Research. 2009 ; Vol. 50, No. 11. pp. 2245-2257.
@article{4673e74db141407f97f5c03a36b0f3d5,
title = "Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies",
abstract = "Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid involved in multiple physiological processes. Importantly, dysregulated S1P levels are associated with several pathologies, including cardiovascular and inflammatory diseases and cancer. This report describes the successful production and characterization of a murine monoclonal antibody, LT1002, directed against S1P, using novel immunization and screening methods applied to bioactive lipids. We also report the successful generation of LT1009, the humanized variant of LT1002, for potential clinical use. Both LT1002 and LT1009 have high affinity and specificity for S1P and do not cross-react with structurally related lipids. Using an in vitro bioassay, LT1002 and LT1009 were effective in blocking S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells, showing that both antibodies can outcompete S1P receptors in binding to S1P. In vivo anti-angiogenic activity of all antibody variants was demonstrated using the murine choroidal neovascularization model. Importantly, intravenous administration of the antibodies showed a marked effect on lymphocyte trafficking. The resulting lead candidate, LT1009, has been formulated for Phase 1 clinical trials in cancer and age-related macular degeneration. The anti-S1P antibody shows promise as a novel, first-in-class therapeutic acting as a {"}molecular sponge{"} to selectively deplete S1P from blood and other compartments where pathological S1P levels have been implicated in disease progression or in disorders where immune modulation may be beneficial.",
keywords = "Age related macular degeneration, Angiogenesis, Bioactive lipids, Cancer, Choroidal neovascularization, Complementarity determining region, Humanization, Lymphocyte trafficking, Monoclonal antibodies, Sphingosine-1-phosphate",
author = "Nicole O'Brien and Jones, {S. Tarran} and Williams, {David G.} and Cunningham, {H. Brad} and Kelli Moreno and Barbara Visentin and Angela Gentile and John Vekich and William Shestowsky and Masao Hiraiwa and Rosalia Matteo and Amy Cavalli and Douglas Grotjahn and Maria Grant and Genevi{\`e}ve Hansen and Campbell, {Mary Ann} and Roger Sabbadini",
year = "2009",
doi = "10.1194/jlr.M900048-JLR200",
language = "English (US)",
volume = "50",
pages = "2245--2257",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies

AU - O'Brien, Nicole

AU - Jones, S. Tarran

AU - Williams, David G.

AU - Cunningham, H. Brad

AU - Moreno, Kelli

AU - Visentin, Barbara

AU - Gentile, Angela

AU - Vekich, John

AU - Shestowsky, William

AU - Hiraiwa, Masao

AU - Matteo, Rosalia

AU - Cavalli, Amy

AU - Grotjahn, Douglas

AU - Grant, Maria

AU - Hansen, Geneviève

AU - Campbell, Mary Ann

AU - Sabbadini, Roger

PY - 2009

Y1 - 2009

N2 - Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid involved in multiple physiological processes. Importantly, dysregulated S1P levels are associated with several pathologies, including cardiovascular and inflammatory diseases and cancer. This report describes the successful production and characterization of a murine monoclonal antibody, LT1002, directed against S1P, using novel immunization and screening methods applied to bioactive lipids. We also report the successful generation of LT1009, the humanized variant of LT1002, for potential clinical use. Both LT1002 and LT1009 have high affinity and specificity for S1P and do not cross-react with structurally related lipids. Using an in vitro bioassay, LT1002 and LT1009 were effective in blocking S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells, showing that both antibodies can outcompete S1P receptors in binding to S1P. In vivo anti-angiogenic activity of all antibody variants was demonstrated using the murine choroidal neovascularization model. Importantly, intravenous administration of the antibodies showed a marked effect on lymphocyte trafficking. The resulting lead candidate, LT1009, has been formulated for Phase 1 clinical trials in cancer and age-related macular degeneration. The anti-S1P antibody shows promise as a novel, first-in-class therapeutic acting as a "molecular sponge" to selectively deplete S1P from blood and other compartments where pathological S1P levels have been implicated in disease progression or in disorders where immune modulation may be beneficial.

AB - Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid involved in multiple physiological processes. Importantly, dysregulated S1P levels are associated with several pathologies, including cardiovascular and inflammatory diseases and cancer. This report describes the successful production and characterization of a murine monoclonal antibody, LT1002, directed against S1P, using novel immunization and screening methods applied to bioactive lipids. We also report the successful generation of LT1009, the humanized variant of LT1002, for potential clinical use. Both LT1002 and LT1009 have high affinity and specificity for S1P and do not cross-react with structurally related lipids. Using an in vitro bioassay, LT1002 and LT1009 were effective in blocking S1P-mediated release of the pro-angiogenic and prometastatic cytokine, interleukin-8, from human ovarian carcinoma cells, showing that both antibodies can outcompete S1P receptors in binding to S1P. In vivo anti-angiogenic activity of all antibody variants was demonstrated using the murine choroidal neovascularization model. Importantly, intravenous administration of the antibodies showed a marked effect on lymphocyte trafficking. The resulting lead candidate, LT1009, has been formulated for Phase 1 clinical trials in cancer and age-related macular degeneration. The anti-S1P antibody shows promise as a novel, first-in-class therapeutic acting as a "molecular sponge" to selectively deplete S1P from blood and other compartments where pathological S1P levels have been implicated in disease progression or in disorders where immune modulation may be beneficial.

KW - Age related macular degeneration

KW - Angiogenesis

KW - Bioactive lipids

KW - Cancer

KW - Choroidal neovascularization

KW - Complementarity determining region

KW - Humanization

KW - Lymphocyte trafficking

KW - Monoclonal antibodies

KW - Sphingosine-1-phosphate

UR - http://www.scopus.com/inward/record.url?scp=70350399322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350399322&partnerID=8YFLogxK

U2 - 10.1194/jlr.M900048-JLR200

DO - 10.1194/jlr.M900048-JLR200

M3 - Article

C2 - 19509417

AN - SCOPUS:70350399322

VL - 50

SP - 2245

EP - 2257

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 11

ER -